[1]张喜芬,赵保礼,杨立波,等.通络明目胶囊治疗糖尿病视网膜病变的随机双盲对照研究[J].西部中医药,2013,26(11):88-90.
　ZHANG Xifen,ZHAO Baoli,YANG Libo,et al.A Randomized, Double-blind and Placebo-controlled Study of TongLuo MingMu Capsule in Treating Diabetic Retinopathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):88-90.
点击复制

通络明目胶囊治疗糖尿病视网膜病变的随机双盲对照研究
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年11期
页码:
88-90
栏目:
出版日期:
2013-11-15

文章信息/Info

Title:
A Randomized, Double-blind and Placebo-controlled Study of TongLuo MingMu Capsule in Treating Diabetic Retinopathy
文章编号:
1004-6852(2013)11-0088-03
作者:
张喜芬1，赵保礼2，杨立波1，田野1，刘晓飞1
1 河北以岭医药研究院，河北 石家庄 050035； 2 河北医科大学第一医院
Author(s):
ZHANG Xifen1, ZHAO Baoli2, YANG Libo1, TIAN Ye1, LIU Xiaofei1
1 Hebei Yiling Pharmaceutical Academy, Shijiazhuang 050035, China; 2 The First Hospital of Hebei Medical University
关键词:
2型糖尿病; 糖尿病视网膜病变; 通络明目胶囊; 羟苯磺酸钙胶囊
Keywords:
diabetes mellitus type 2;  diabetic retinopathy;  TongLuo MingMu capsule;  calcium dobesilate capsule
分类号:
R276.17
文献标志码:
A
摘要:
目的：评价通络明目胶囊治疗糖尿病视网膜病变的有效性和安全性。方法：采用平行对照、随机、双盲临床试验方法，将146例受试者随机分为试验组和对照组，分别服用通络明目胶囊和羟苯磺酸钙胶囊治疗，疗程均为12周。结果：疾病综合疗效试验组为73.91%，对照组为72.31%；中医证候疗效试验组为89.86%；对照组为73.85%。2组比较疾病综合疗效差异无统计学意义(P＞0.05)。结论：通络明目胶囊治疗糖尿病视网膜病变疗效与羟苯磺酸钙胶囊相当，且不良反应发生率低。
Abstract:
Objective: To evaluate the safety and effectiveness of TongLuo MingMu capsule for the treatment of diabetic retinopathy(DR). Method: All 146 patients were randomized into the experiment group and the control group through parallel controlled, randomized, double-blind clinical trial. Both groups took TongLuo MingMu capsule and calcium dobesilate capsule respectively, the therapy lasted 12 weeks. Result: Comprehensive effect of the experiment group was 73.91%, higher than 72.31% of the control group; TCM effects of both groups were 89.86% and 73.85%. The difference had no statistical meaning between both groups in comprehensive effects of the disease (P＞0.05). Conclusion: Curative effects of TongLuo MingMu capsule are notable in treating DR, similar to calcium dobesilate capsule but with lower incidence of adverse reaction.

相似文献/References:

[1]祁瑞芳.同型半胱氨酸、超敏 C- 反应蛋白在 2 型糖尿病合并脑梗死预测中的作用[J].西部中医药,2014,27(08):152.
[2]邱勇玉,李应东,赵信科,等.高血压病中医证型与 2 型糖尿病及其相关危险因素分析[J].西部中医药,2014,27(09):75.
[3]李东峰,指导：王志刚.王志刚主任医师治疗2型糖尿病“三级”防治思想辨治心得[J].西部中医药,2015,28(01):29.
[4]周雨聪,指导：刘召.红灵五黄汤治疗2型糖尿病90例[J].西部中医药,2015,28(04):99.
[5]杨国军.黄芪注射液对2型糖尿病患者血管功能及微循环状态的影响[J].西部中医药,2015,28(05):109.
[6]康学东,张瀚文.病证结合探讨2型糖尿病胰岛素抵抗[J].西部中医药,2015,28(11):112.
[7]戴梅.全面干预护理对2型糖尿病患者血糖和糖化血红蛋白水平的影响[J].西部中医药,2013,26(07):109.
　DAI Mei.Intervention of Comprehensive Nursing on Blood Glucose and Glycosylated Hemoglobin of Patients with Diabetes Mellitus Type Two[J].Western Journal of Traditional Chinese Medicine,2013,26(11):109.
[8]罗向霞,张定华,史晓伟,等.糖网康对非增殖期糖尿病视网膜功能保护作用的实验研究*[J].西部中医药,2014,27(08):11.
　LUO Xiangxia,ZHANG Dinghua,SHI Xiaowei,et al.Experimental Study on TangWangKang Protecting Retinal Function of the Patients with Diabetes Mellitus at Non-proliferation Phase[J].Western Journal of Traditional Chinese Medicine,2014,27(11):11.
[9]段俊国,罗向霞△,许国旺,等.DR病情进展与阳虚病机关系的研究[J].西部中医药,2013,26(08):1.
　DUAN Junguo,LUO Xiangxia,XU Guowang,et al.Study on the Relationship between the Progression and Yang-deficiency Mechanism of Diabetic Retinopathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):1.
[10]张家林,裴瑞霞.银花痛风颗粒治疗2型糖尿病合并高尿酸血症疗效观察[J].西部中医药,2014,27(01):106.
　ZHANG Jialin,PEI Ruixia.Clinical Observation on YinHua TongFeng Granules in Treating Type 2 Diabetes Mellitus Complicated with Hyperuricemia[J].Western Journal of Traditional Chinese Medicine,2014,27(11):106.

备注/Memo

备注/Memo:
收稿日期：2013-05-04 作者简介：张喜芬(1979—)，女，硕士学位，主治医师。研究方向：中成药的新药研发。
更新日期/Last Update: 2013-11-15